- Home
- SNN vs MEDP Comparison
SNN vs MEDP Comparison
Compare SNN & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNN
- MEDP
- Stock Information
- Founded
- SNN 1856
- MEDP 1992
- Country
- SNN United Kingdom
- MEDP United States
- Employees
- SNN N/A
- MEDP N/A
- Industry
- SNN Industrial Specialties
- MEDP Biotechnology: Commercial Physical & Biological Resarch
- Sector
- SNN Health Care
- MEDP Health Care
- Exchange
- SNN Nasdaq
- MEDP Nasdaq
- Market Cap
- SNN 15.2B
- MEDP 13.4B
- IPO Year
- SNN 1999
- MEDP 2016
- Fundamental
- Price
- SNN $33.23
- MEDP $589.15
- Analyst Decision
- SNN Hold
- MEDP Hold
- Analyst Count
- SNN 4
- MEDP 11
- Target Price
- SNN $33.50
- MEDP $451.70
- AVG Volume (30 Days)
- SNN 681.6K
- MEDP 350.9K
- Earning Date
- SNN 10-30-2025
- MEDP 10-22-2025
- Dividend Yield
- SNN 2.20%
- MEDP N/A
- EPS Growth
- SNN 59.91
- MEDP 25.36
- EPS
- SNN 0.56
- MEDP 14.32
- Revenue
- SNN $5,944,000,000.00
- MEDP $2,358,373,000.00
- Revenue This Year
- SNN $7.85
- MEDP $21.48
- Revenue Next Year
- SNN $5.43
- MEDP $11.90
- P/E Ratio
- SNN $28.79
- MEDP $41.14
- Revenue Growth
- SNN 5.35
- MEDP 13.88
- 52 Week Low
- SNN $23.69
- MEDP $250.05
- 52 Week High
- SNN $38.79
- MEDP $625.00
- Technical
- Relative Strength Index (RSI)
- SNN 33.56
- MEDP 62.02
- Support Level
- SNN $31.83
- MEDP $572.12
- Resistance Level
- SNN $37.06
- MEDP $602.54
- Average True Range (ATR)
- SNN 0.54
- MEDP 20.93
- MACD
- SNN -0.33
- MEDP -0.69
- Stochastic Oscillator
- SNN 24.43
- MEDP 59.40
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
About MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.